Ovarian neoplasm
MONDO:0021068A benign, borderline, or malignant neoplasm involving the ovary.
Also known as: neoplasm of ovary, neoplasm of the ovary, ovarian neoplasm, ovarian tumor, ovarian tumors, ovarian tumour, ovarian tumours, ovary neoplasm
2508 clinical trials for this condition and its sub-types, 78 tagged with Ovarian neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Ovarian neoplasm
-
Ovarian cancer 1,002 trials · 1,198 incl. sub-types
11 sub-types
- Malignant epithelial tumor of ovary 8 trials · 656 incl. sub-types Sub-types →
- Malignant non-epithelial tumor of ovary 1 trial · 9 incl. sub-types Sub-types →
- Familial ovarian cancer 1 trial · 8 incl. sub-types Sub-types →
- Ovarian neuroendocrine neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Ovarian sarcoma 0 trials · 2 incl. sub-types Sub-types →
- Malignant ovarian cyst 1 trial
- Ovarian Wilms tumor 0 trials
- Ovarian adenosarcoma 0 trials
- Ovarian endometrioid adenocarcinofibroma 0 trials
- Ovarian lymphoma 0 trials
- Ovarian malignant mesothelioma 0 trials
-
Ovarian epithelial tumor 14 trials · 664 incl. sub-types
11 sub-types
- Malignant epithelial tumor of ovary 8 trials · 656 incl. sub-types Sub-types →
- Ovarian serous tumor 6 trials · 207 incl. sub-types Sub-types →
- Ovarian clear cell tumor 7 trials · 57 incl. sub-types Sub-types →
- Borderline epithelial tumor of ovary 6 trials · 16 incl. sub-types Sub-types →
- Ovarian mucinous neoplasm 1 trial · 16 incl. sub-types Sub-types →
- Ovarian seromucinous tumor 1 trial · 14 incl. sub-types Sub-types →
- Ovarian Brenner tumor 3 trials · 5 incl. sub-types Sub-types →
- Ovarian papillary tumor 0 trials · 2 incl. sub-types Sub-types →
- Ovarian squamous cell neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Ovarian adenoma benign 0 trials Sub-types →
- Ovarian mucinous adenofibroma 0 trials Sub-types →
-
Ovarian germ cell tumor 9 trials · 13 incl. sub-types
4 sub-types
- Malignant germ cell tumor of ovary 2 trials · 4 incl. sub-types Sub-types →
- Ovarian teratoma 0 trials · 3 incl. sub-types Sub-types →
- Pediatric ovarian germ cell tumor 0 trials · 2 incl. sub-types Sub-types →
- Ovarian cystic teratoma 0 trials Sub-types →
-
Ovarian sex cord-stromal tumor 1 trial · 7 incl. sub-types
6 sub-types
- Malignant sex cord stromal tumor of ovary 0 trials · 5 incl. sub-types Sub-types →
- Ovarian granulosa cell tumor 2 trials · 5 incl. sub-types Sub-types →
- Ovarian sertoli-stromal cell tumor 0 trials · 1 incl. sub-types Sub-types →
- Benign ovarian sex cord-stromal tumor 0 trials Sub-types →
- Ovarian gynandroblastoma 0 trials
- Ovarian thecoma 0 trials
-
Ovarian benign neoplasm 1 trial
15 sub-types
- Meigs syndrome 0 trials
- Atypical Meigs syndrome 0 trials
- Benign ovarian mucinous tumor 0 trials
- Benign ovarian sex cord-stromal tumor 0 trials Sub-types →
- Benign struma ovarii 0 trials
- Ovarian adenoma benign 0 trials Sub-types →
- Ovarian clear cell adenofibroma 0 trials Sub-types →
- Ovarian endometrioid adenofibroma 0 trials Sub-types →
- Ovarian fibroma 0 trials
- Ovarian mucinous adenofibroma 0 trials Sub-types →
- Ovarian serous adenofibroma 0 trials Sub-types →
- Ovarian surface papilloma 0 trials
- Pseudo-Meigs syndrome 0 trials
- Rete ovarii cystadenofibroma 0 trials
- Serous or mucinous cystadenoma of childhood 0 trials Sub-types →
-
Ovarian melanoma 0 trials
-
Rete ovarii neoplasm 0 trials
3 sub-types
- Rete ovarii adenocarcinoma 0 trials
- Rete ovarii adenoma 0 trials Sub-types →
- Rete ovarii cystadenofibroma 0 trials
Most studied deeper sub-types
-
New drug combo aims to keep ovarian cancer at bay
Disease control Recruiting nowThis Phase 3 trial tests whether a targeted therapy called sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer without their cancer growing. About 900 participants who have finished initial chemotherapy will…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New hope for ovarian cancer: phase 3 trial tests targeted drug against Tough-to-Treat tumors
Disease control Recruiting nowThis large Phase 3 study tests a new medicine called Sofetabart Mipitecan for people with ovarian, fallopian tube, or peritoneal cancer. It includes two groups: those whose cancer stopped responding to platinum chemotherapy within six months (platinum-resistant), and those whose …
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New radioactive drug targets FAP-Positive tumors in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug, LY4170156, designed to attack cancer cells with a specific marker (folate receptor alpha). It is for people with advanced solid tumors like ovarian, lung, or breast cancer that have not responded to other treatments. The trial has two parts: first fin…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Could existing cancer drugs tackle rare tumors? new trial aims to find out
Disease control Recruiting nowThis trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…
Phase 2/3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug combo trial aims to fight advanced cancers
Disease control Recruiting nowThis study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…
Phase 1/2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New drug DM002 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…
Phase 1/2 • Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: experimental drug enters human trials
Disease control Recruiting nowThis early-stage study tests a new drug called PF-08046054/SGN-PDL1V, alone or with another drug (pembrolizumab), in people with advanced solid tumors like lung, head and neck, esophageal, breast, stomach, endometrial, pancreatic, or liver cancer. The main goals are to find safe …
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for tough ovarian cancer: phase 3 trial of Mo-Rez drug launches
Disease control Recruiting nowThis study tests a new drug called mocertatug rezetecan (Mo-Rez) in 450 people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if Mo-Rez helps people live longer without their cancer growing compared to standard treatments. Researchers…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New cancer drug sigvotatug vedotin enters human trials
Disease control Recruiting nowThis early-stage trial is testing a new drug called sigvotatug vedotin, alone or with other cancer medicines, in people with advanced solid tumors like lung, head and neck, and breast cancers. The study aims to find a safe dose and check for side effects. About 1,000 participants…
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Cancer drug niraparib gets Long-Term safety check in extension trial
Disease control Recruiting nowThis study offers continued access to niraparib, a daily oral cancer drug, for up to 37 patients with ovarian or breast cancer who have already completed a prior niraparib trial and are still benefiting. The main goal is to monitor long-term safety, including side effects and cha…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Smart immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…
Phase 1/2 • Sponsor: A2 Biotherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New antibody drug aims to unleash immune system on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug, UCB4594, in people with advanced solid tumors that haven't responded to standard treatments. The drug is a monoclonal antibody that targets a protein called HLA-G on cancer cells, potentially helping the immune system attack them. The stud…
Phase 1/2 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for rare ovarian cancer: immunotherapy combo tested in phase II trial
Disease control Recruiting nowThis phase II trial is testing whether the immunotherapy drug dostarlimab, alone or combined with bevacizumab, can control recurrent gynecological clear cell carcinoma better than standard chemotherapy. About 198 women with this rare cancer type will be randomly assigned to one o…
Phase 2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, find…
Phase 1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a breast cancer drug combo treat rare tumors?
Disease control Recruiting nowThis trial tests two drugs, trastuzumab and pertuzumab, already approved for breast cancer, in people with rare cancers that have a specific genetic change called HER2 amplification or mutation. About 30 adults and children with various rare or hard-to-treat cancers will receive …
Phase 2/3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a melanoma drug combo tame rare BRAF cancers?
Disease control Recruiting nowThis trial is testing two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific genetic change called BRAF V600 mutation. The goal is to see if the combination can shrink tumors or stop them from growing. About 3…
Phase 2/3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New ultrasound technique could sharpen ovarian cancer detection
Diagnosis Recruiting nowThis study tests a new ultrasound technique called microvessel imaging (UMI) to see if it can better detect small blood vessels in ovarian lesions, which may indicate cancer. Forty women scheduled for ovarian surgery will receive both standard and UMI ultrasounds. Doctors will co…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 09:01 UTC
-
Could a simple injection replace major surgery for ovarian cancer staging?
Diagnosis Recruiting nowThis study tests a sentinel lymph node technique, where a small amount of radioactive tracer and dye is injected to find the first lymph nodes that might contain cancer. In 200 women with early-stage ovarian cancer, doctors will compare this method to the standard approach of rem…
Phase 3 • Sponsor: Instituto de Investigacion Sanitaria La Fe • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Could a simple wash catch ovarian cancer before it spreads?
Diagnosis Recruiting nowThis study is testing a new way to detect ovarian cancer early. Researchers will take a sample of fluid from the womb (uterine lavage) and a blood sample from 250 women before they have surgery for a suspected ovarian growth. After surgery, they will check whether the woman had c…
Sponsor: Massachusetts General Hospital • Aim: Diagnosis
Last updated Jun 26, 2026 17:54 UTC
-
New tool aims to improve talks between ovarian cancer patients and doctors
Symptom relief Recruiting nowThis study tests a tool called CASI that helps ovarian cancer patients, their caregivers, and doctors set a shared plan for each visit. The goal is to see if using this tool is practical and helpful. About 112 people with advanced ovarian cancer and their caregivers will take par…
Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New coaching program aims to boost quality of life for ovarian cancer survivors
Symptom relief Recruiting nowThis study tests a coaching program called POSTCARE-O for women with ovarian cancer who have finished their initial treatment. The program provides support during the transition to survivorship, focusing on quality of life and emotional well-being. 120 women will be randomly assi…
Sponsor: Baylor College of Medicine • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Acupuncture meets medicine: new combo targets Post-Surgery nausea
Symptom relief Recruiting nowThis study tests whether adding a gentle electrical acupoint stimulation (TEAS) to a standard three-drug anti-nausea regimen can further reduce vomiting after laparoscopic surgery. Researchers will compare active TEAS to a sham (fake) version in 780 women at high risk for postope…
Sponsor: Zhejiang University • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Can a smartwatch track how kids recover from cancer surgery?
Knowledge-focused Recruiting nowThis study is testing whether smartwatches and blood tests can measure how well children recover after surgery to remove a solid tumor. About 40 children and their caregivers will wear smartwatches and answer questionnaires before surgery and for up to a year after. Researchers w…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Could a simple dye replace major surgery for ovarian cancer staging?
Knowledge-focused Recruiting nowThis study looks at whether a blue dye injected into the ovary can help doctors find the first lymph node where cancer might spread, instead of removing many lymph nodes. The goal is to see if this less invasive method works as well as standard surgery for early-stage ovarian can…
Sponsor: Faculty of Medicine of Tunis • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
New study gathers key materials to create personalized cell therapies for tough cancers
Knowledge-focused Recruiting nowThis observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Could centralized surgery boost ovarian cancer survival?
Knowledge-focused Recruiting nowThis study examines whether concentrating ovarian cancer surgery in specialized centers and changes in treatment during the COVID-19 pandemic affect how long patients live without their cancer returning. Researchers will follow about 200 women diagnosed with epithelial ovarian ca…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Mice with human tumors could unlock personalized cancer therapies
Knowledge-focused Recruiting nowThis study takes tumor samples from people with triple-negative breast cancer, colorectal cancer, or ovarian cancer and grows them in mice. Researchers then test different drugs on these mouse tumors to see which ones might work best for each person. The goal is to provide person…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New cancer registry aims to unlock secrets of ovarian and endometrial cancer treatment
Knowledge-focused Recruiting nowThis study is a large German registry that will follow nearly 2,000 people with advanced ovarian or endometrial cancer. Researchers will collect information on the treatments patients actually receive, how their disease responds, and their quality of life. The goal is to understa…
Sponsor: iOMEDICO AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
MRI tool may help surgeons avoid unnecessary ovary removal in girls
Knowledge-focused Recruiting nowThis study looks at whether a special MRI scoring system called O-RADS can accurately tell if an ovarian mass in girls under 16 is cancerous or not. Researchers will review the MRIs of 100 girls who had surgery for ovarian masses at two hospitals. The goal is to see if this tool …
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Scientists probe immune weakness in ovarian cancer to unlock new treatments
Knowledge-focused Recruiting nowThis study aims to understand why the immune system fails to fight ovarian cancer effectively. Researchers will compare blood, bone marrow, and immune cells from 90 women with ovarian cancer and healthy controls. The goal is to find ways to reprogram immune cells to attack the tu…
Sponsor: Gynaecologisch Oncologisch Centrum Zuid • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC